Becton Dickinson & Co (BDX)
230.48
-3.35
(-1.43%)
USD |
NYSE |
Apr 25, 16:00
230.46
-0.02
(-0.01%)
Pre-Market: 20:00
Becton Dickinson Research and Development Expense (Quarterly): 290.00M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 290.00M |
| September 30, 2023 | 281.00M |
| June 30, 2023 | 306.00M |
| March 31, 2023 | 337.00M |
| December 31, 2022 | 313.00M |
| September 30, 2022 | 300.00M |
| June 30, 2022 | 315.00M |
| March 31, 2022 | 327.00M |
| December 31, 2021 | 314.00M |
| September 30, 2021 | 368.00M |
| June 30, 2021 | 330.00M |
| March 31, 2021 | 317.00M |
| December 31, 2020 | 291.00M |
| September 30, 2020 | 242.00M |
| June 30, 2020 | 262.00M |
| March 31, 2020 | 264.00M |
| December 31, 2019 | 270.00M |
| September 30, 2019 | 270.00M |
| June 30, 2019 | 282.00M |
| March 31, 2019 | 252.00M |
| December 31, 2018 | 258.00M |
| September 30, 2018 | 277.00M |
| June 30, 2018 | 277.00M |
| March 31, 2018 | 259.00M |
| December 31, 2017 | 191.00M |
| Date | Value |
|---|---|
| September 30, 2017 | 216.00M |
| June 30, 2017 | 186.00M |
| March 31, 2017 | 187.00M |
| December 31, 2016 | 182.00M |
| September 30, 2016 | 253.00M |
| June 30, 2016 | 207.00M |
| March 31, 2016 | 182.00M |
| December 31, 2015 | 187.00M |
| September 30, 2015 | 196.00M |
| June 30, 2015 | 178.00M |
| March 31, 2015 | 129.00M |
| December 31, 2014 | 129.00M |
| September 30, 2014 | 140.00M |
| June 30, 2014 | 137.00M |
| March 31, 2014 | 147.00M |
| December 31, 2013 | 126.00M |
| September 30, 2013 | 132.00M |
| June 30, 2013 | 121.00M |
| March 31, 2013 | 122.00M |
| December 31, 2012 | 118.00M |
| September 30, 2012 | 128.03M |
| June 30, 2012 | 114.99M |
| March 31, 2012 | 116.75M |
| December 31, 2011 | 112.23M |
| September 30, 2011 | 125.01M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
242.00M
Minimum
Sep 2020
368.00M
Maximum
Sep 2021
298.89M
Average
300.00M
Median
Sep 2022
Research and Development Expense (Quarterly) Benchmarks
| AngioDynamics Inc | 8.189M |
| West Pharmaceutical Services Inc | 18.40M |
| Integer Holdings Corp | 13.26M |
| Merit Medical Systems Inc | 21.64M |
| Insulet Corp | 42.00M |